NASDAQ:DBVT DBV Technologies (DBVT) Stock Forecast, Price & News $1.96 +0.02 (+0.77%) (As of 02:32 PM ET) Add Compare Share Share Today's Range$1.91▼$2.0050-Day Range$1.42▼$2.2352-Week Range$1.08▼$3.43Volume50,847 shsAverage Volume92,792 shsMarket Capitalization$369.95 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media DBV Technologies MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside245.4% Upside$6.67 Price TargetShort InterestBearish0.91% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.51) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.41 out of 5 starsMedical Sector1877th out of 1,980 stocksBiological Products, Except Diagnostic Industry313th out of 330 stocks 3.3 Analyst's Opinion Consensus RatingDBV Technologies has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.67, DBV Technologies has a forecasted upside of 245.4% from its current price of $1.93.Amount of Analyst CoverageDBV Technologies has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted0.91% of the outstanding shares of DBV Technologies have been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 24.7, which indicates bearish sentiment.Change versus previous monthShort interest in DBV Technologies has recently increased by 2.40%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDBV Technologies does not currently pay a dividend.Dividend GrowthDBV Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DBVT. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for DBV Technologies this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added DBV Technologies to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DBV Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.71% of the stock of DBV Technologies is held by insiders.Percentage Held by InstitutionsOnly 18.37% of the stock of DBV Technologies is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DBV Technologies are expected to grow in the coming year, from ($0.51) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV Technologies is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV Technologies is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV Technologies has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DBV Technologies (NASDAQ:DBVT) StockDBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.Read More Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DBVT Stock News HeadlinesMay 26, 2023 | americanbankingnews.comDBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.comMay 20, 2023 | americanbankingnews.comStockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)June 1, 2023 | Edge On The Street (Ad)AI Getting Close to Thinking Like HumansTechnology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.May 13, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for DBV Technologies S.A. Lowered by HC Wainwright (NASDAQ:DBVT)May 12, 2023 | finance.yahoo.comA simple skin patch shows promise for preventing peanut allergiesMay 12, 2023 | americanbankingnews.comHC Wainwright Comments on DBV Technologies S.A.'s FY2026 Earnings (NASDAQ:DBVT)May 11, 2023 | marketwatch.comDBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin(TM) Peanut in ToddlersMay 11, 2023 | markets.businessinsider.comGood News For Toddlers With Peanut Allergy: DBVT Data Shows Promising Results for Peanut Allergy PatchJune 1, 2023 | Edge On The Street (Ad)ChatGPT Is Already "Old School"As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.May 11, 2023 | americanbankingnews.comDBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.comMay 11, 2023 | markets.businessinsider.comJMP Securities Sticks to Its Buy Rating for DBV Technologies SA – American (DBVT)May 10, 2023 | finance.yahoo.comDBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in ToddlersMay 10, 2023 | americanbankingnews.comDBV Technologies S.A. (NASDAQ:DBVT) Receives $6.67 Average PT from BrokeragesMay 9, 2023 | markets.businessinsider.comDBV Technologies SA – American (DBVT) Gets a Buy from H.C. WainwrightMay 5, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on DBV Technologies SA – American (DBVT)May 4, 2023 | finance.yahoo.comDBV Technologies Reports First Quarter 2023 Financial ResultsApril 30, 2023 | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) vs. DBV Technologies (NASDAQ:DBVT) Critical ComparisonApril 20, 2023 | marketwatch.comDBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 - 3 Years After Receiving Pre-BLA Responses from FDAApril 19, 2023 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 - 3 Years After Receiving Pre-BLA Responses from FDAApril 19, 2023 | finance.yahoo.comDBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDAApril 17, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)April 13, 2023 | americanbankingnews.comBrokerages Set DBV Technologies S.A. (NASDAQ:DBVT) Target Price at $6.67April 12, 2023 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General MeetingApril 12, 2023 | finance.yahoo.comDBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General MeetingApril 9, 2023 | americanbankingnews.comDBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.comMarch 24, 2023 | finance.yahoo.comOrdinary and Extraordinary General Meeting of April 12, 2023March 13, 2023 | finance.yahoo.comDBV Technologies UpdateSee More Headlines DBVT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DBVT Company Calendar Last Earnings5/04/2023Today6/01/2023Next Earnings (Estimated)8/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DBVT CUSIPN/A CIK1613780 Webwww.dbv-technologies.com Phone(315) 542-7878Fax33-1-43-26-10-83Employees92Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.67 High Stock Price Forecast$10.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+241.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,270,000.00 Net Margins-778.60% Pretax Margin-2,228.93% Return on Equity-48.25% Return on Assets-39.56% Debt Debt-to-Equity RatioN/A Current Ratio6.41 Quick Ratio6.41 Sales & Book Value Annual Sales$4.84 million Price / Sales75.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book2.05Miscellaneous Outstanding Shares188,270,000Free Float187,144,000Market Cap$367.13 million OptionableOptionable Beta1.27 Key ExecutivesDaniel TasséChief Executive Officer & Executive DirectorSébastien RobitailleChief Financial OfficerPharis MohideenChief Medical OfficerPascal WotlingChief Technical Operations & Quality OfficerPascale EhouarnChief Engineering, Manufacturing & Supply OfficerKey CompetitorsAlloVirNASDAQ:ALVRbluebird bioNASDAQ:BLUECompass TherapeuticsNASDAQ:CMPXCoherus BioSciencesNASDAQ:CHRSHumacyteNASDAQ:HUMAView All CompetitorsInstitutional OwnershipAmeriprise Financial Inc.Sold 41,812 shares on 5/22/2023Ownership: 0.639%BlackRock Inc.Sold 81,420 shares on 5/12/2023Ownership: 0.517%OLD Mission Capital LLCBought 21,694 shares on 5/12/2023Ownership: 0.016%View All Institutional Transactions DBVT Stock - Frequently Asked Questions Should I buy or sell DBV Technologies stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DBVT shares. View DBVT analyst ratings or view top-rated stocks. What is DBV Technologies' stock price forecast for 2023? 5 brokers have issued 1-year price objectives for DBV Technologies' stock. Their DBVT share price forecasts range from $4.00 to $10.00. On average, they predict the company's stock price to reach $6.67 in the next twelve months. This suggests a possible upside of 241.9% from the stock's current price. View analysts price targets for DBVT or view top-rated stocks among Wall Street analysts. How have DBVT shares performed in 2023? DBV Technologies' stock was trading at $1.53 at the beginning of 2023. Since then, DBVT stock has increased by 27.5% and is now trading at $1.95. View the best growth stocks for 2023 here. When is DBV Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023. View our DBVT earnings forecast. How were DBV Technologies' earnings last quarter? DBV Technologies S.A. (NASDAQ:DBVT) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.14. The company earned $2.19 million during the quarter, compared to analyst estimates of $1.30 million. DBV Technologies had a negative net margin of 778.60% and a negative trailing twelve-month return on equity of 48.25%. What other stocks do shareholders of DBV Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO). What is DBV Technologies' stock symbol? DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT." Who are DBV Technologies' major shareholders? DBV Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Ameriprise Financial Inc. (0.64%), BlackRock Inc. (0.52%) and OLD Mission Capital LLC (0.02%). How do I buy shares of DBV Technologies? Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DBV Technologies' stock price today? One share of DBVT stock can currently be purchased for approximately $1.95. How much money does DBV Technologies make? DBV Technologies (NASDAQ:DBVT) has a market capitalization of $367.13 million and generates $4.84 million in revenue each year. The company earns $-96,270,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. How can I contact DBV Technologies? DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The official website for the company is www.dbv-technologies.com. The company can be reached via phone at (315) 542-7878, via email at sara.sherman@dbv-technologies.com, or via fax at 33-1-43-26-10-83. This page (NASDAQ:DBVT) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.